initial results of zuma-3 trial ‘highly encouraging’ for relapsed, refractory leukemia
Published 4 years ago • 58 plays • Length 6:37Download video MP4
Download video MP3
Similar videos
-
7:06
zuma-3: a study of kte-c19 in adults with relapsed/refractory acute lymphoblastic leukaemia
-
2:48
results from a subgroup analysis of zuma-3 and the efficacy of brexu-cel in r/r b-all
-
6:24
zuma-3 study update: brexucabtagene autoleucel for r/r all
-
1:40
dr. shah on results of zuma-3 study for all
-
12:08
zuma-3 trial update of brexucabtagene autoleucel in adult patients with r/r b-all
-
0:54
zuma-3 end of phase i results: axi-cel for r/r all
-
7:57
two-year follow-up of zuma-3: safety and efficacy of brexu-cel in patients with r/r b-all
-
1:59
efficacy and safety of cd19-targeted car t-cells for relapsed/refractory all
-
2:23
zuma-3 update: prior blinatumomab does not alter car t-cell efficacy in all
-
23:38
relapsed all/acute lymphoblastic leukemia /inotuzumab ozogomycin#car-t/inovate trial#critical review
-
3:54
zuma-2: outcomes of r/r mcl patients who progressed within 24 months of diagnosis
-
1:12
status of the zuma-3 trial of car t-cell product kte-c19 for r/r all
-
1:22
the importance of finding strategies to prevent relapse of acute myeloid leukemia (aml)
-
2:22
the treatment of relapsed/refractory chronic lymphocytic leukemia
-
48:39
thursday webinar - management of relapsed/refractory acute lymphoblastic leukaemia in adult
-
2:19
zuma-3: identifying the optimal dose of axi-cel in r/r all
-
5:40
approaching treatment for relapsed/refractory all
-
1:17
dr. deangelo on inotuzumab ozogamicin for relapsed/refractory all
-
0:48
managing patients with t-all who relapse or are refractory to first-line treatment